SCHEMBL5332845

SCHEMBL5332845

Cc1nc(Oc2ccccc2)c(NCCCCl)c(N)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17A Q9UEE5 2/20 0.38
STK17B O94768 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
TLR8 Q9NR97 3/20 0.34
TLR7 Q9NYK1 3/20 0.34
ALDH1A1 P00352 2/20 0.33
KMT2A Q03164 2/20 0.33
SCN5A Q14524 1/20 0.33
SCN9A Q15858 1/20 0.33
MRGPRX1 Q96LB2 1/20 0.33
ADORA2A P29274 1/20 0.33
MEN1 O00255 1/20 0.33
TOP2A P11388 1/20 0.33
CYP1A2 P05177 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
TRPA1 O75762 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5343269 0.96 STK17A (0.37) STK17ASTK17BLMNAHTTTLR8
SCHEMBL4769232 0.95 STK17A (0.36) STK17ASTK17BLMNAHTTTLR8
Hydrochloric Acid SCHEMBL4773467 0.79 PIN1 (0.40) LMNAHTTALDH1A1KMT2AADORA2A
SCHEMBL4777348 0.79 GBA1 (0.36) LMNAHTTTLR8TLR7ALDH1A1
SCHEMBL5117067 0.79 MAPT (0.39) LMNAHTTTLR7ALDH1A1ADORA2A
SCHEMBL4772034 0.79 HTR7 (0.42) ALDH1A1NPC1RAB9A
SCHEMBL1232939 0.77 TOP2A (0.37) ALDH1A1KMT2ATOP2A
SCHEMBL28753431 0.77 TOP2A (0.37) ALDH1A1KMT2ATOP2A
SCHEMBL4768129 0.77 PIN1 (0.40) LMNAHTTALDH1A1KMT2AADORA2A
SCHEMBL4765985 0.76 PIN1 (0.39) LMNAHTTALDH1A1KMT2AADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed
US-6797718-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-28 US disclosed
US-20040010007-A1 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 STK17A 2212/4885STK17B 2490/4885LMNA 4400/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP STK17A 1233/4885STK17B 1840/4885LMNA 4818/4885
US-20040010007-A1 Ether substituted imidazopyridines IL2, IL4, MYD88 STK17A 2212/4885STK17B 2490/4885LMNA 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.